Palmoplantar keratoderma, Nagashima type
palm-oh-plan-tar ker-uh-toe-der-ma, nah-gah-shee-ma type
Also known as: Nagashima-type palmoplantar keratosis, NPPK
At a Glance
What is Palmoplantar keratoderma, Nagashima type?
Nagashima-type palmoplantar keratoderma is a genetic skin disorder that primarily affects the palms of the hands and the soles of the feet. It is caused by mutations in the SERPINB7 gene, leading to thickening of the skin in these areas. The condition usually begins in childhood and progresses over time, with skin becoming increasingly thick and scaly. Early symptoms include mild redness and scaling, while later symptoms involve more pronounced thickening and potential cracking of the skin. Early diagnosis is important to manage symptoms and prevent complications such as infections. The condition can impact family life due to the need for regular skin care and potential mobility issues. Prognosis is generally good with proper management, though the condition is lifelong. Daily life for affected individuals involves regular moisturizing and protective measures to prevent skin damage. The disorder does not typically affect life expectancy. It can be socially and emotionally challenging due to visible skin changes. Support from healthcare providers and family is crucial in managing the condition.
Medical Definition
Nagashima-type palmoplantar keratoderma is a genetic disorder characterized by diffuse hyperkeratosis of the palms and soles due to mutations in the SERPINB7 gene. Pathologically, it involves abnormal keratinization and thickening of the stratum corneum. Histological findings include orthokeratotic hyperkeratosis and acanthosis. It is classified under the group of palmoplantar keratodermas, with a higher prevalence in East Asian populations. The disease course is chronic and progressive, with symptoms typically appearing in early childhood. Management focuses on symptomatic relief and preventing secondary complications.
Palmoplantar keratoderma, Nagashima type Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
This symptom manifests as a noticeable thickening of the skin on the palms of the hands and soles of the feet. The biological mechanism involves mutations in the SERPINB7 gene, leading to abnormal keratinization. Over time, the thickening may become more pronounced and can lead to fissures or cracks. This affects daily life by causing discomfort or pain during activities such as walking or grasping objects, and regular moisturizing and keratolytic agents can help manage it.
Hyperkeratosis presents as an excessive buildup of keratin on the skin surface, leading to a rough texture. It is caused by an overproduction of keratin due to genetic mutations affecting skin cell turnover. The condition can worsen with age or environmental factors like friction. Patients may experience difficulty in performing manual tasks, and treatments include topical retinoids or salicylic acid to reduce skin thickness.
Fissuring occurs when the thickened skin on the palms and soles cracks, creating painful splits. This happens due to the rigidity and reduced elasticity of hyperkeratotic skin. Without intervention, fissures can deepen and lead to secondary infections. Daily activities such as walking or handling objects can become painful, and management involves keeping the skin well-moisturized and protected.
Common
Redness and inflammation are often seen around areas of thickened skin, indicating underlying irritation. This results from the body's immune response to the abnormal skin barrier. Over time, inflammation can lead to further skin damage if not managed. It can cause discomfort and itching, and anti-inflammatory treatments such as topical corticosteroids may be used.
Pain is a common symptom due to the pressure and tension on thickened skin, especially during movement. It arises from nerve irritation and micro-tears in the skin. The intensity of pain can increase with physical activity or prolonged standing. Pain management includes the use of analgesics and protective padding to reduce pressure.
Blistering may occur in response to friction or pressure on the thickened skin areas. This is due to the separation of skin layers caused by weakened structural integrity. Blisters can become more frequent with increased physical activity. They can lead to discomfort and potential infection, so protective footwear and blister care are recommended.
Less Common
Nail abnormalities can include thickening, discoloration, or ridging of the nails. These changes occur due to the same keratinization defects affecting the skin. Over time, nail changes can become more pronounced and affect nail growth. They may cause cosmetic concerns and discomfort, and treatment focuses on regular nail care and monitoring.
Itching is a less common symptom but can occur due to dry and irritated skin. It is caused by the release of inflammatory mediators in response to skin barrier disruption. Persistent itching can lead to scratching and further skin damage. Antihistamines and emollients can be used to alleviate itching and protect the skin.
What Causes Palmoplantar keratoderma, Nagashima type?
Nagashima-type palmoplantar keratoderma is primarily caused by mutations in the SERPINB7 gene, located on chromosome 18q21.3. The SERPINB7 gene encodes a member of the serine protease inhibitor family, which plays a crucial role in protecting tissues from proteolytic damage. Mutations in SERPINB7 can lead to misfolding of the protein, impairing its ability to inhibit target proteases effectively. This disruption results in unregulated protease activity, causing degradation of structural proteins in the skin. Consequently, there is a breakdown of the skin barrier, leading to hyperkeratosis and thickening of the palms and soles. The inflammatory response is triggered as immune cells attempt to repair the damaged tissue, contributing to further skin changes. Neuroinflammation is not a primary feature, but immune-mediated mechanisms may exacerbate skin pathology. The degeneration of skin structures is localized to palms and soles due to the high mechanical stress and unique keratin composition in these areas. Variability in disease severity among patients may be attributed to differences in mutation type, environmental factors, and genetic background. Some patients may experience spontaneous remission, suggesting a complex interplay between genetic and environmental factors. The specific pattern of symptoms is due to the localized expression of SERPINB7 and the unique structural demands of palmoplantar skin. Immune response modulation and protease activity are key factors in the progression and variability of the disease. Understanding the precise molecular pathways involved could lead to targeted therapies that address both the genetic and inflammatory components of the disease.
How is Palmoplantar keratoderma, Nagashima type Diagnosed?
Typical age of diagnosis: Nagashima-type palmoplantar keratoderma is typically diagnosed in childhood or early adolescence, often when patients present with thickened skin on the palms and soles. Diagnosis is usually prompted by the characteristic appearance of the skin and a family history of similar symptoms.
Clinicians look for thickened, hyperkeratotic skin on the palms and soles, often with a yellowish hue. A detailed family history is crucial, as the condition is inherited in an autosomal recessive manner. Physical examination reveals symmetrical involvement of the palms and soles, sometimes extending to the dorsal surfaces. This step helps differentiate Nagashima-type from other forms of keratoderma.
Imaging studies are not typically used in the diagnosis of Nagashima-type palmoplantar keratoderma. However, if performed, high-resolution ultrasound might show thickened stratum corneum. These findings can support the diagnosis but are not definitive. Imaging helps exclude other conditions with similar presentations, such as plantar fibromatosis.
Routine laboratory tests are not specific for this condition, but skin biopsy can be performed. Histopathology may reveal hyperkeratosis and acanthosis. These results are non-specific but can rule out other dermatological conditions. Laboratory findings guide the clinician toward genetic testing for confirmation.
Genetic testing focuses on sequencing the SERPINB7 gene. Mutations such as missense or nonsense mutations in this gene confirm the diagnosis. Identification of these mutations provides a definitive diagnosis and informs genetic counseling for the family. This step is crucial for understanding inheritance patterns and recurrence risks.
Palmoplantar keratoderma, Nagashima type Treatment Options
Keratolytic agents such as salicylic acid and urea are commonly used. They work by softening and breaking down the keratin in the skin. Topical retinoids may also be prescribed to reduce hyperkeratosis. Clinical evidence suggests moderate efficacy in reducing skin thickness. Side effects can include skin irritation and peeling.
Emollient therapy involves the regular application of moisturizing creams to the affected areas. The goal is to maintain skin hydration and reduce scaling. Sessions should be frequent, ideally daily, and ongoing. Measurable outcomes include improved skin texture and reduced fissuring. Long-term benefits include enhanced skin barrier function.
Surgical debridement may be indicated for severe cases with painful fissures. The procedure involves the careful removal of thickened skin layers. Expected benefits include pain relief and improved mobility. Surgical risks include infection and scarring. Post-operative care involves wound management and continued use of emollients.
A multidisciplinary team may include dermatologists, genetic counselors, and physical therapists. Interventions focus on skin care management and genetic counseling. Psychosocial support strategies are essential for patient and family coping. Family education includes guidance on condition management and genetic implications. Long-term monitoring ensures timely intervention for complications.
When to See a Doctor for Palmoplantar keratoderma, Nagashima type
- Severe skin infection — This is an emergency because it can lead to systemic infection and requires immediate medical intervention.
- Rapidly worsening pain or swelling in the hands or feet — This could indicate a severe complication or secondary infection that needs urgent care.
- High fever with skin symptoms — This may suggest a serious infection or inflammatory response requiring emergency evaluation.
- Persistent cracking or bleeding of the skin — This is concerning as it may lead to infection; consult a dermatologist for management.
- New or worsening skin lesions — This could indicate disease progression or complications; seek medical advice.
- Uncontrolled itching or discomfort — This can significantly impact quality of life and may require treatment adjustment.
- Mild dryness or scaling — Monitor for changes and maintain regular moisturizing routines at home.
- Occasional mild itching — Keep track of triggers and manage with over-the-counter treatments as needed.
Palmoplantar keratoderma, Nagashima type — Frequently Asked Questions
Is this condition hereditary?
Nagashima-type palmoplantar keratoderma is inherited in an autosomal recessive pattern. This means both parents must carry a copy of the mutated gene for a child to be affected. De novo mutations are rare in this condition. Carriers typically do not show symptoms but can pass the gene to offspring. Genetic counseling is recommended for families to understand inheritance risks and carrier status.
What is the life expectancy for someone with this condition?
Life expectancy is generally normal for individuals with Nagashima-type palmoplantar keratoderma. Early onset may lead to more severe symptoms, but it does not typically affect overall survival. Mortality is not directly caused by the condition but can be influenced by secondary infections. Effective management and treatment can improve quality of life but do not significantly alter lifespan. Patients should have realistic expectations regarding symptom management rather than life expectancy.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves clinical evaluation, family history, and genetic testing to confirm mutations in the SERPINB7 gene. The time from first symptoms to diagnosis can vary, often taking several months due to symptom overlap with other conditions. Dermatologists and geneticists are typically consulted for diagnosis. Delays often occur due to misdiagnosis or lack of awareness. Genetic testing provides definitive confirmation of the condition.
Are there any new treatments or clinical trials available?
Research is ongoing, with promising studies focusing on gene therapy and novel topical treatments. Clinical trials can be found on ClinicalTrials.gov by searching for 'Nagashima-type palmoplantar keratoderma'. Patients should discuss potential trial participation with their doctors. New treatments are still in experimental stages, with timelines for availability varying. Staying informed about research developments is crucial for accessing future therapies.
How does this condition affect daily life and activities?
Nagashima-type palmoplantar keratoderma can impact mobility due to painful skin on the hands and feet. Educational activities may be affected by discomfort or the need for frequent medical appointments. Social and emotional challenges include coping with visible symptoms and potential stigma. Family members may bear additional caregiving responsibilities. Supportive footwear, regular skincare routines, and psychological support can significantly improve daily life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Nagashima-type palmoplantar keratoderma.
Chen TL, Li CY · Indian J Dermatol Venereol Leprol · 2025 · PMID: 39635795
- 2.History and prospects of Nagashima-type palmoplantar keratosis, the most common palmoplantar keratoderma in east Asian populations.
Kubo A · J Dermatol · 2025 · PMID: 39749860
- 3.Nagashima-Type Palmoplantar Keratosis: Clinical Characteristics, Genetic Characterization, and Clinical Management.
Huang C, Yang Y, Huang X et al. · Biomed Res Int · 2021 · PMID: 33575348
- 4.Investigation of Nagashima-type palmoplantar keratoderma in China: A cross-sectional study of 234 patients.
Liu J, Chen Z, Hu L et al. · J Dermatol · 2023 · PMID: 36317385
- 5.SERPINA12 variants harboured in Nagashima-type palmoplantar keratoderma: Potential inflammatory characteristics.
Zhang C, Wang Y, Cao Q et al. · J Dermatol Sci · 2025 · PMID: 40312186
- 6.Nagashima-type palmoplantar keratoderma: Case series and two novel variants.
Braun M, Choate KA, Mathes EF · Pediatr Dermatol · 2023 · PMID: 36721328
- 7.SERPINB7 mutation causes Nagashima-type palmoplantar keratosis and its spatiotemporal expression in zebrafish.
Lyu C, Zhang F, Liu T et al. · Exp Dermatol · 2023 · PMID: 36772997
- 8.Spontaneous clinical remission of Nagashima-type palmoplantar keratoderma in a patient of Korean descent with a heterozygous SERPINB7 mutation.
Thakker S, Owusu-Agyei M, Marchalik R et al. · Pediatr Dermatol · 2024 · PMID: 38165066
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-09